309 related articles for article (PubMed ID: 26828145)
1. FDG PET/CT Evidence of Effective Treatment of Cardiac Sarcoidosis With Adalimumab.
Miller CT; Sweiss NJ; Lu Y
Clin Nucl Med; 2016 May; 41(5):417-8. PubMed ID: 26828145
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis.
Rosenthal DG; Parwani P; Murray TO; Petek BJ; Benn BS; De Marco T; Gerstenfeld EP; Janmohamed M; Klein L; Lee BK; Moss JD; Scheinman MM; Hsia HH; Selby V; Koth LL; Pampaloni MH; Zikherman J; Vedantham V
J Am Heart Assoc; 2019 Sep; 8(18):e010952. PubMed ID: 31538835
[TBL] [Abstract][Full Text] [Related]
3. Refractory polymyalgia rheumatica as presenting manifestation of large-vessel vasculitis associated to sarcoidosis. Successful response to adalimumab.
Bejerano C; Blanco R; González-Vela C; Agüero R; Carril JM; González-Gay MA
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S94-7. PubMed ID: 22410180
[TBL] [Abstract][Full Text] [Related]
4. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET.
Milman N; Graudal N; Loft A; Mortensen J; Larsen J; Baslund B
Clin Respir J; 2012 Oct; 6(4):238-47. PubMed ID: 22128762
[TBL] [Abstract][Full Text] [Related]
5. Serial FDG-PET scans help to identify steroid resistance in cardiac sarcoidosis.
Shelke AB; Aurangabadkar HU; Bradfield JS; Ali Z; Kumar KS; Narasimhan C
Int J Cardiol; 2017 Feb; 228():717-722. PubMed ID: 27886616
[TBL] [Abstract][Full Text] [Related]
6. MRI and FDG PET/CT imaging manifestations of cardiac sarcoidosis.
Lu Y; Sweiss NJ
Clin Nucl Med; 2015 Dec; 40(12):973-4. PubMed ID: 26544904
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET and MIBI-Tc SPECT as follow-up tools in a patient with cardiac sarcoidosis requiring a pacemaker.
Smedema JP; White L; Klopper AJ
Cardiovasc J Afr; 2008; 19(6):309-10. PubMed ID: 19104727
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic involvement detected with (18)F-FDG PET/CT in disseminated sarcoidosis.
Delgado-Bolton RC; Arias Navalón JA; Rodríguez Alfonso B; Delgado-Bolton AN; Pérez-Castejón MJ; Sánchez-Escribano R; Cabrera Martín MN; Lapeña Gutiérrez L; Carreras Delgado JL
Rev Esp Med Nucl; 2011; 30(1):29-32. PubMed ID: 20638156
[TBL] [Abstract][Full Text] [Related]
9. Clinical Response to Tumor Necrosis Factor-α Inhibitor Therapy in the Management of Cardiac Sarcoidosis.
Churchill R; Sykora D; Castrichini M; Arment C; Myasoedova E; Elwazir M; Bois J; Young K; Rosenbaum A
Am J Cardiol; 2023 Oct; 205():20-27. PubMed ID: 37579656
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Myocardial 18F-FDG Uptake Through Prolonged High-Fat, High-Protein, and Very-Low-Carbohydrate Diet Before FDG-PET/CT for Evaluation of Patients With Suspected Cardiac Sarcoidosis.
Lu Y; Grant C; Xie K; Sweiss NJ
Clin Nucl Med; 2017 Feb; 42(2):88-94. PubMed ID: 27922863
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG PET/CT for the assessment of myocardial sarcoidosis.
Skali H; Schulman AR; Dorbala S
Curr Cardiol Rep; 2013 May; 15(5):352. PubMed ID: 23504346
[TBL] [Abstract][Full Text] [Related]
12. Use of integrated FDG-PET/CT in sarcoidosis.
Krüger S; Buck AK; Mottaghy FM; Pauls S; Schelzig H; Hombach V; Reske SN
Clin Imaging; 2008; 32(4):269-73. PubMed ID: 18603181
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of heparin loading during an 18F-FDG PET/CT examination to search for cardiac sarcoidosis activity.
Ito K; Morooka M; Okazaki O; Minaminoto R; Kubota K; Hiroe M
Clin Nucl Med; 2013 Feb; 38(2):128-30. PubMed ID: 23334129
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of cardiac sarcoidosis despite negative findings on serial late gadolinium enhancement with cardiac magnetic resonance imaging/
Tanaka TD; Nagai T; Nagoshi T; Yoshimura M
J Nucl Cardiol; 2020 Dec; 27(6):2149-2153. PubMed ID: 31773564
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis.
Bolat S; Berding G; Dengler R; Stangel M; Trebst C
J Neurol Sci; 2009 Dec; 287(1-2):257-9. PubMed ID: 19755199
[TBL] [Abstract][Full Text] [Related]
16. Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis.
Ohira H; Birnie DH; Pena E; Bernick J; Mc Ardle B; Leung E; Wells GA; Yoshinaga K; Tsujino I; Sato T; Manabe O; Oyama-Manabe N; Nishimura M; Tamaki N; Dick A; Dennie C; Klein R; Renaud J; deKemp RA; Ruddy TD; Chow BJW; Davies R; Hessian R; Liu P; Beanlands RSB; Nery PB
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):259-269. PubMed ID: 26359191
[TBL] [Abstract][Full Text] [Related]
17. Assessment of treatment response in cardiac sarcoidosis based on myocardial
Frischknecht L; Schaab J; Schmauch E; Yalamanoglu A; Arnold DD; Schwaiger J; Gruner C; Buechel RR; Franzen DP; Kolios AGA; Nilsson J
Front Immunol; 2023; 14():1286684. PubMed ID: 38077350
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis.
Tahara N; Tahara A; Nitta Y; Kodama N; Mizoguchi M; Kaida H; Baba K; Ishibashi M; Hayabuchi N; Narula J; Imaizumi T
JACC Cardiovasc Imaging; 2010 Dec; 3(12):1219-28. PubMed ID: 21163450
[TBL] [Abstract][Full Text] [Related]
19. F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis.
Simonen P; Lehtonen J; Kandolin R; Schildt J; Marjasuo S; Miettinen H; Airaksinen J; Vihinen T; Tuohinen S; Haataja P; Kupari M
Am J Cardiol; 2015 Nov; 116(10):1581-5. PubMed ID: 26411357
[TBL] [Abstract][Full Text] [Related]
20. The Utility of Whole Body
Giudicatti L; Marangou J; Nolan D; Dembo L; Baumwol J; Dwivedi G
Heart Lung Circ; 2020 Jan; 29(1):e1-e6. PubMed ID: 31501049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
